Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

372 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Frequency and prognostic significance of t(v;11q23)/KMT2A rearrangements in adult patients with acute lymphoblastic leukemia treated with risk-adapted protocols.
Motlló C, Ribera JM, Morgades M, Granada I, Montesinos P, Brunet S, Bergua J, Tormo M, García-Boyero R, Sarrà J, Del Potro E, Grande C, Barba P, Bernal T, Amigo ML, Grau J, Cervera J, Feliu E; PETHEMA Group, Spanish Society of Hematology. Motlló C, et al. Among authors: cervera j. Leuk Lymphoma. 2017 Jan;58(1):145-152. doi: 10.1080/10428194.2016.1177182. Epub 2016 Apr 27. Leuk Lymphoma. 2017. PMID: 27122129
Prolonged molecular remission after PML/RAR alpha-positive autologous peripheral blood stem cell transplantation in acute promyelocytic leukemia: is relevant pretransplant minimal residual disease in the graft?
Sanz MA, de la Rubia J, Bonanad S, Barragán E, Sempere A, Martín G, Martínez JA, Jiménez C, Cervera J, Bolufer P, Sanz GF. Sanz MA, et al. Among authors: cervera j. Leukemia. 1998 Jun;12(6):992-5. doi: 10.1038/sj.leu.2401024. Leukemia. 1998. PMID: 9639431
Autologous blood stem cell transplantation for acute myeloblastic leukemia in first complete remission. Intensification therapy before transplantation does not prolong disease-free survival.
de la Rubia J, Sanz GF, Martín G, Martínez J, Cervera J, Solves P, Jiménez C, Arnao M, Vicente A, Jarque I, Sempere A, Sanz MA. de la Rubia J, et al. Among authors: cervera j. Haematologica. 1999 Feb;84(2):125-32. Haematologica. 1999. PMID: 10091410 Clinical Trial.
Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes. Grupo Cooperativo Español de Citogenética Hematológica.
Solé F, Espinet B, Sanz GF, Cervera J, Calasanz MJ, Luño E, Prieto F, Granada I, Hernández JM, Cigudosa JC, Diez JL, Bureo E, Marqués ML, Arranz E, Ríos R, Martínez Climent JA, Vallespí T, Florensa L, Woessner S. Solé F, et al. Among authors: cervera j. Br J Haematol. 2000 Feb;108(2):346-56. doi: 10.1046/j.1365-2141.2000.01868.x. Br J Haematol. 2000. PMID: 10691865 Free article.
Additional cytogenetic changes do not influence the outcome of patients with newly diagnosed acute promyelocytic leukemia treated with an ATRA plus anthracyclin based protocol. A report of the Spanish group PETHEMA.
Hernández JM, Martín G, Gutiérrez NC, Cervera J, Ferro MT, Calasanz MJ, Martínez-Climent JA, Luño E, Tormo M, Rayón C, Díaz-Mediavilla J, González M, González-San Miguel JD, Pérez-Equiza K, Rivas C, Esteve J, Alvarez Mdel C, Odriozola J, Ribera JM, Sanz MA; PETHA Cooperative Group, Spain. Hernández JM, et al. Among authors: cervera j. Haematologica. 2001 Aug;86(8):807-13. Haematologica. 2001. PMID: 11522536
MLL amplification in acute myeloid leukemia.
Pajuelo-Gámez JC, Cervera J, García-Casado Z, Mena-Durán AV, Valencia A, Barragán E, Such E, Bolufer P, Sanz MA. Pajuelo-Gámez JC, et al. Among authors: cervera j. Cancer Genet Cytogenet. 2007 Apr 15;174(2):127-31. doi: 10.1016/j.cancergencyto.2006.11.019. Cancer Genet Cytogenet. 2007. PMID: 17452254
372 results